Last reviewed · How we verify
abatacept (ABA)
Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.
Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.
At a glance
| Generic name | abatacept (ABA) |
|---|---|
| Also known as | Orencia, BMS-188667 |
| Sponsor | Bristol-Myers Squibb |
| Drug class | CTLA-4 immunoglobulin fusion protein |
| Target | CD80/CD86 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Abatacept works by interrupting the second signal required for full T-cell activation. It consists of the extracellular domain of CTLA-4 fused to the Fc portion of IgG1, allowing it to bind CD80 and CD86 molecules on antigen-presenting cells. This prevents the interaction between these molecules and CD28 on T cells, effectively suppressing the adaptive immune response in autoimmune conditions.
Approved indications
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Systemic lupus erythematosus
Common side effects
- Infections (upper respiratory, urinary tract)
- Headache
- Nausea
- Dizziness
- Hypertension
Key clinical trials
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT (EARLY_PHASE1)
- COVID-19 VaccinE Response in Rheumatology Patients (PHASE4)
- Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (PHASE2)
- A Study of Abatacept in Patients With Active Ulcerative Colitis (PHASE3)
- Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis (PHASE3)
- Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy (PHASE3)
- Remission and Joint Damage Progression in Early Rheumatoid Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- abatacept (ABA) CI brief — competitive landscape report
- abatacept (ABA) updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI